{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["65(3)"],"submitter":["Sautto GA"],"pubmed_abstract":["<h4>Objective</h4>The recent availability of novel antiviral drugs has raised new hope for a more effective treatment of hepatitis C virus (HCV) infection and its severe sequelae. However, in the case of non-responding or relapsing patients, alternative strategies are needed. To this end we have used chimeric antigen receptors (CARs), a very promising approach recently used in several clinical trials to redirect primary human T cells against different tumours. In particular, we designed the first CARs against HCV targeting the HCV/E2 glycoprotein (HCV/E2).<h4>Design</h4>Anti-HCV/E2 CARs were composed of single-chain variable fragments (scFvs) obtained from a broadly cross-reactive and cross-neutralising human monoclonal antibody (mAb), e137, fused to the intracellular signalling motif of t"],"journal":["Gut"],"pagination":["512-23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4789830"],"repository":["biostudies-literature"],"pubmed_title":["Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein."],"pmcid":["PMC4789830"],"pubmed_authors":["Sautto GA","Protzer U","Diotti RA","Burioni R","Graf J","Mancini N","Wisskirchen K","Clementi N","Castelli M","Clementi M"],"additional_accession":[]},"is_claimable":false,"name":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.","description":"<h4>Objective</h4>The recent availability of novel antiviral drugs has raised new hope for a more effective treatment of hepatitis C virus (HCV) infection and its severe sequelae. However, in the case of non-responding or relapsing patients, alternative strategies are needed. To this end we have used chimeric antigen receptors (CARs), a very promising approach recently used in several clinical trials to redirect primary human T cells against different tumours. In particular, we designed the first CARs against HCV targeting the HCV/E2 glycoprotein (HCV/E2).<h4>Design</h4>Anti-HCV/E2 CARs were composed of single-chain variable fragments (scFvs) obtained from a broadly cross-reactive and cross-neutralising human monoclonal antibody (mAb), e137, fused to the intracellular signalling motif of t","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Mar","modification":"2026-05-05T17:37:29.157Z","creation":"2019-03-26T22:42:35Z"},"accession":"S-EPMC4789830","cross_references":{"pubmed":["25661083"],"doi":["10.1136/gutjnl-2014-308316"]}}